How to buy EyePoint Pharmaceuticals stock | $11.52

EyePoint Pharmaceuticals Inc is a biotechnology business based in the US. EyePoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. EyePoint Pharmaceuticals employs 98 staff and has a trailing 12-month revenue of around 0.00.

EyePoint Pharmaceuticals stock price (NASDAQ: EYPT)

Use our graph to track the performance of EYPT stocks over time.

EyePoint Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-25.

Latest market close	$11.52
52-week range	$3.51 - $15.06
50-day moving average	$10.82
200-day moving average	$9.71
Wall St. target price	$21.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.06

Buy EyePoint Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy EyePoint Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

EyePoint Pharmaceuticals price performance over time

Historical closes compared with the close of $11.52 from 2021-10-25

1 week (2021-10-19)	-3.44%
1 month (2021-09-24)	-1.71%
3 months (2021-07-26)	44.72%
6 months (2021-04-26)	11.95%

1 year (2020-10-26)	2,706.33%
2 years (2019-10-25)	423.64%
3 years (2018-10-26)	418.92%
5 years (2016-10-26)	430.88%

EyePoint Pharmaceuticals financials

Revenue TTM	$39.2 million
Gross profit TTM	$11.2 million
Return on assets TTM	-18.12%
Return on equity TTM	-74.85%
Profit margin	-106.12%
Book value	$3.72
Market capitalisation	$345.5 million

TTM: trailing 12 months

Shorting EyePoint Pharmaceuticals shares

There are currently 1.4 million EyePoint Pharmaceuticals shares held short by investors – that's known as EyePoint Pharmaceuticals's "short interest". This figure is 3.7% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting EyePoint Pharmaceuticals shares can be evaluated.

EyePoint Pharmaceuticals's "short interest ratio" (SIR)

EyePoint Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyePoint Pharmaceuticals shares currently shorted divided by the average quantity of EyePoint Pharmaceuticals shares traded daily (recently around 117600). EyePoint Pharmaceuticals's SIR currently stands at 11.64. In other words for every 100,000 EyePoint Pharmaceuticals shares traded daily on the market, roughly 11640 shares are currently held short.

However EyePoint Pharmaceuticals's short interest can also be evaluated against the total number of EyePoint Pharmaceuticals shares, or, against the total number of tradable EyePoint Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyePoint Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 EyePoint Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0639% of the tradable shares (for every 100,000 tradable EyePoint Pharmaceuticals shares, roughly 64 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against EyePoint Pharmaceuticals.

Find out more about how you can short EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals share dividends

We're not expecting EyePoint Pharmaceuticals to pay a dividend over the next 12 months.

Have EyePoint Pharmaceuticals's shares ever split?

EyePoint Pharmaceuticals's shares were split on a 1:10 basis on 8 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyePoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for EyePoint Pharmaceuticals shares which in turn could have impacted EyePoint Pharmaceuticals's share price.

EyePoint Pharmaceuticals share price volatility

Over the last 12 months, EyePoint Pharmaceuticals's shares have ranged in value from as little as $3.511 up to $15.06. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyePoint Pharmaceuticals's is 1.255. This would suggest that EyePoint Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

EyePoint Pharmaceuticals overview

EyePoint Pharmaceuticals, Inc. , a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc. , Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc.

Frequently asked questions

What percentage of EyePoint Pharmaceuticals is owned by insiders or institutions?
Currently 12.584% of EyePoint Pharmaceuticals shares are held by insiders and 74.757% by institutions. How many people work for EyePoint Pharmaceuticals?
Latest data suggests 98 work at EyePoint Pharmaceuticals. When does the fiscal year end for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals's fiscal year ends in December. Where is EyePoint Pharmaceuticals based?
EyePoint Pharmaceuticals's address is: 480 Pleasant Street, Watertown, MA, United States, 02472 What is EyePoint Pharmaceuticals's ISIN number?
EyePoint Pharmaceuticals's international securities identification number is: US30233G2093 What is EyePoint Pharmaceuticals's CUSIP number?
EyePoint Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 30233G100